摘要
目的:探讨复方参仲口服液抗大鼠骨质疏松的作用。方法:采用连续灌胃14 d维甲酸建立大鼠骨质疏松模型,30 d后处死大鼠,取血液作各项有关的生化指标检查,并取左股骨进行骨密度(BMD)的测定,用右股骨作骨组织形态计量学观察,并与注射苯甲酸雌二醇的阳性对照组及服用复方参仲口服液治疗各组比较。结果:与空白组相比,模型组的大鼠出现明显的骨质疏松,而复方参仲口服液治疗各组对大鼠骨质疏松有明显的拮抗作用;复方参仲口服液可时抗维甲酸的抑制体重的作用,提高大鼠骨干重量及骨密度,改善碱性磷酸酶含量及骨组织形态使骨小梁个数增多。结论:复方参仲口服液能改善维甲酸所致的大鼠骨质疏松。
Objective： To investigate the antiosteoporosis effects of compound shenzhong oral solution. Method： Osteoporosis rats models were established by ig retinoic acid for 14 days. After one month, all the rats were killed, and the blood were collected, the bone of the left and right legs were measured. The results were compared with the estradiol benzoate（ E2 ） group and treated groups. Resuit： Compared with the blank control group, model group appear osteoporosis significantly. Compound shenzhong oral solution groups had obvious antagonize effect to osteoporosis, and could antagonize the effects of control avoirdupois. Shaft of bone weight and BMD in rats were raised, the ALP content and bone tissue form were ameliorated, and bone trabeculas piece was increased. Conclusion： Compound shenzhong oral solution could improve the osteoporosis rats models of retinoic acid.
出处
《中国药师》
CAS
2007年第4期305-308,共4页
China Pharmacist
基金
广西壮族自治区科技厅课题(编号:桂科攻0161011)
关键词
骨质疏松
复方参仲口服液
维甲酸
Osteoporosis
Compound shenzhong oral solution
Retinoic acid
